Biopharma News

A gene therapy developer has received funding for trials of its new treatment for beta-thalassmia.

The cost of medicine in the UK is among the lowest of all developed nations.

Biogen enjoyed strong results in the third quarter of 2012.

GlycanMap will be used in the search of new biomarkers for MS.

The BioIndustry Association has welcomed a consultation on proposals to clarify the legal framework within which researchers operate with regard to intellectual property.

BioLine has announced plans to conduct an interim analysis of current Phase II and III trials of BL-1020, its orally available GABA-enhanced antipsychotic for treatment of schizophrenia. The analysis will take place in the coming months, with a complet...

DSM will manufacture recombinant human follistatin at its facility in Brisbane.

Pfizer has announced its intention to exercise its option to acquire NextWave Pharmaceuticals.

A study by Cutting Edge Information has revealed the importance of confidential pricing agreements when launching a new product.

There has been a noticeable shift towards ensuring patients get the most out of their medication.

Setting aside a dedicated budget for medical publication tends to be associated with a higher output of manuscripts and abstracts, a report has shown.

New excipients will be on show at a pharmaceuticals event in Madrid later this month.

BioSante and ANI have announced a merger agreement and will form a new combined company.

Adoption of biosimilars is expected to be rapid in the US - at least in the field of nephrology.

Takeda is to acquire LigoCyte Pharmaceuticals and its norovirus vaccine candidate.

TransCelerate BioPharma is a non-profit organisation set up by ten biopharmaceutical giants.

China wants to become a major developer of vaccines for the developing world.

Eutropics will provide its BH3 profiling diagnostic assay to the NCI.

BioLineRx has reported positive results from Phase II testing of its new schizophrenia treatment BL-1020.

Colorcon will provide customers with access to expertise on film coating formulation processes for Quality by Design (QbD) requirements.

BioTime has established a new subsidiary to oversee its strategic acquisitions.

Novo Nordisk is investing in the Chinese biopharmaceuticals supply chain with the establishment of a new research and development centre.

Watson Pharmaceuticals believes it is entitled to shared marketing exclusivity on generic Actos.

Whether to insource or outsource the production of sterile injectable drugs is influenced by capacity.

Aquapharm Biodiscovery believes the marine-derived compound AQP-182 could help to tackle multi-drug resistant bacteria.

Biotechs are finding it increasingly difficult to secure partnering deals with pharmaceutical companies.

Paragon Bioservices would license and use CEVEC's know-how and patents to develop stable cell lines and perform process development for the contract manufacturing of recombinant proteins and antibodies.

Parexel's new dedicated unit will meet the needs of small biopharmaceutical companies.

iBio and GE Healthcare are working together to develop a single facility for the manufacturing of plant-based biotherapeutics and vaccines.

There has been a fall in venture capital investment in the life sciences industry in the US.

There are almost 200 biopharmaceutical products for mental illness in development in the US at this time.

Neviah Genomics is a new company being created by Compugen and Merck Serono.

A survey has highlighted the challenges faced by life sciences companies with regard to document management.

Swiss-based Debiopharm Group and China's Ascepion Pharmaceuticals hope to bring a new anti-cancer drug to market.

DSM Pharmaceutical Products has announced that several countries have granted patents or have given statements of patent allowance to its proprietary XD? high cell density process technology.

A new collaboration between BioInvent, Cancer Research Technology and Queen Mary, University of London will aim to speed up the discovery and development of new cancer treatments.

Biopharmaceutical services company Quintiles has highlighted the need for drugmakers to adapt their marketing strategies.

Stemcell Technologies is adding a series of new products to its portfolio of high quality cell culture media for stem cell scientists.

BioCryst is streamlining its portfolio of antivirals in a bid to lower costs.

The objective of this joint programme is to promote and fund market-driven research and technology development as well as to encourage partnerships and business-led R&D&I collaborative projects in the field of biotechnology.

Open and frequent communication is vitally important for the success of partnerships between pharmaceutical and biotech companies.

Teralys Capital and Eli Lilly and Company have invested in a new $150m life sciences fund.

France Biotech and Ernst & Young's latest report looks at the state of the French biotech industry.

The latest report from biopharmaceutical services company Quintiles has looked at the subject of drug development risk.

Corporate venture funding is a good predictor for licensing deals, acquisition and IPOs, an analysis has revealed.

A report suggests that America's biopharmaceutical dominance could be under threat as countries around the world are investing in the sector.

Drug developer Kythera Biopharmaceuticals is to go public in a bid to generate funds for its ongoing clinical development of aesthetic medicine ATX-101.

Biotechnology companies - particularly smaller outfits - should benefit from the new patent system being brought in under the America Invents Act.

A new collaboration has been announced between Bristol-Myers Squibb and China's Tsinghua University.

Biopharmaceutical firm Orexigen Therapeutics will be added to the NASDAQ Biotechnology Index effective Monday, May 21, 2012.

A report has highlighted India's potential in the biopharmaceutical industry.

Antisense Pharma has announced the appointment of Dr. Philippe Calais as CEO.

Novo Nordisk will use Caisson's proprietary drug delivery technology to engineer and develop novel therapeutics.

Mucosis has announced the publication of preclinical data showing that FluGEM provides superior cross-protection against influenza virus.

Horizon Discovery and biopharmaceutical company H3 Biomedicine have announced a new collaboration agreement.

A report by Visiongain claims that disposable bioreactor technologies will become more widely used over the coming decade.

A report reveals that there are nearly 300 vaccines in clinical testing or under FDA review at the current time in the US.

Ipsen has opened its new commercial headquarters in Basking Ridge, New Jersey.

Ventria Bioscience is acquiring exclusive ownership rights to intellectual property relating to Meristem Therapeutics' recombinant human lactoferrin.